Phase 1 study of interleukin-12 in combination with rituximab inpatients with B-cell non-Hodgkin's lymphoma

Blood

Volumn 99, Issue 1, 2002, Pages 67-74

  Ansell, Stephen M ^a,b   Witzig, Thomas E ^a   Kurtin, Paul J ^a   Sloan, Jeff A ^a   Jelinek, Diane F ^a   Howell, Kyle G ^a   Markovic, Svetomir N ^a   Habermann, Thomas M ^a   Klee, George G ^a   Atherton, Pamela J ^a   Erlichman, Charles ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INDUCIBLE PROTEIN 10; INTERLEUKIN 12; LIVER ENZYME; PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIVER FUNCTION TEST; MALE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 0036090166     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.67     Document Type: Article

References (44)

1. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
2. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells
3. Interleukin-112: A new clinical player incytokine therapy
4. Interleukin-12
5. Interleukin-12: A recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors
6. Antitumor and anti metastatic-activity of interleukin-12 against murine tumors
7. Inhibition of angiogenesis in vivo by interleukin-12
8. Recombinant IL-12 administration induces tumor regression in association with IFN gamma production
9. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
10. IL-12-induced tumor regression correlates with in situ activity of IFN-γ produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways
11. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes
12. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains
13. Expression of human B-cell-associated antigens on leukemias and lymphomas: A model of human B-cell differentiation
14. The B-cell surface molecule B1 is functionally linked with B-cell activation and differentiation
15. Depletion of B cells in vivo by achimeric mouse human monoclonal antibody to CD20
16. Chimericanti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs
17. Anti-CD20 and B-cell receptor mediated apoptosis: Evidence for shared intracellular signaling pathways
18. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma
19. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
20. Rituximab chimeric anti-CD20 monoclonal anti body therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
21. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
22. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate grade non-Hodgkin's lymphoma after high dose therapy and autologous peripheral stem cell transplantation
23. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
24. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
25. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
26. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
27. Rituximab monoclonal anti body as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma
28. AUK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
29. - T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome
30. Accelerated titration designs for phase I clinical trials in oncology
31. Report of international workshop to standardize response criteria for non-Hodgkin's lymphoma
32. Weighted Kaplan-Meier statistics: A class of distance tests for censored survival data
33. An integrated system for monitoring, reporting and analyzing phase I oncology clinical trials
34. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effect or mechanisms
35. Biologic response of B lymphoma cells to anti-CD20 monoclonal anti body rituximab in vitro: CD55 and CD59-regulate complement-mediated cell lysis
36. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer
37. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies
38. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
39. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
40. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon gamma production
41. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
42. Fc receptor cross-linking in the presence of IL-12 is a potent stimulus to natural killer production of interferon-gamma: Implications for antiher2 antibody therapy
43. Rituximab (anti-CD20 monoclonal anti body) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
44. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses